A randomized trial of icosapent ethyl in ambulatory patients with COVID-19
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A randomized trial of icosapent ethyl in ambulatory patients with COVID-19
Authors
Keywords
-
Journal
iScience
Volume 24, Issue 9, Pages 103040
Publisher
Elsevier BV
Online
2021-08-27
DOI
10.1016/j.isci.2021.103040
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized clinical trial
- (2021) Saeid Doaei et al. Journal of Translational Medicine
- Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid
- (2020) R. Preston Mason et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction
- (2020) Xiaowen Wang et al. Current Diabetes Reports
- Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial
- (2020) Matthew J Budoff et al. EUROPEAN HEART JOURNAL
- Beyond cardiovascular medicine: potential future uses of icosapent ethyl
- (2020) Deepak L Bhatt et al. EUROPEAN HEART JOURNAL SUPPLEMENTS
- Immunity, endothelial injury and complement-induced coagulopathy in COVID-19
- (2020) Luca Perico et al. Nature Reviews Nephrology
- Reduction in Revascularization With Icosapent Ethyl
- (2020) Benjamin E. Peterson et al. CIRCULATION
- Pro resolving inflammatory effects of the lipid mediators of omega 3 fatty acids and its implication in SARS COVID-19
- (2020) Pedro-Antonio Regidor et al. MEDICAL HYPOTHESES
- Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation
- (2020) Stefania Lamon-Fava et al. PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS
- New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease
- (2019) R. Preston Mason Current Atherosclerosis Reports
- Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT
- (2019) Deepak L. Bhatt et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators
- (2018) Charles N. Serhan et al. JOURNAL OF CLINICAL INVESTIGATION
- Reliability, Validity, and Responsiveness of InFLUenza Patient-Reported Outcome (FLU-PRO©) Scores in Influenza-Positive Patients
- (2018) John H. Powers et al. VALUE IN HEALTH
- Using the Influenza Patient-reported Outcome (FLU-PRO) diary to evaluate symptoms of influenza viral infection in a healthy human challenge model
- (2018) Alison Han et al. BMC INFECTIOUS DISEASES
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
- (2018) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Lipid Mediator Protectin D1 Inhibits Influenza Virus Replication and Improves Severe Influenza
- (2013) Masayuki Morita et al. CELL
- Treatment with ω-3 fatty acids reduces serum C-reactive protein concentration
- (2011) Kamran I Muhammad et al. Clinical Lipidology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now